Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 5.6% – Here’s Why

Rapport Therapeutics (NASDAQ:RAPP) traded down 5.6% during mid-day trading on Friday . The company traded as low as $16.05 and last traded at $15.82. 11,780 shares traded hands during mid-day trading, a decline of 88% from the average session volume of 97,091 shares. The stock had previously closed at $16.75.

Rapport Therapeutics Stock Down 2.9 %

The business has a fifty day moving average of $17.37 and a 200-day moving average of $20.34.

Rapport Therapeutics (NASDAQ:RAPP) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.07. As a group, research analysts expect that Rapport Therapeutics will post -3.65 EPS for the current fiscal year.

Institutional Investors Weigh In On Rapport Therapeutics

Several institutional investors have recently bought and sold shares of the company. Squarepoint Ops LLC purchased a new stake in shares of Rapport Therapeutics during the second quarter worth about $380,000. Millennium Management LLC purchased a new position in shares of Rapport Therapeutics during the 2nd quarter valued at approximately $2,716,000. The Manufacturers Life Insurance Company purchased a new position in shares of Rapport Therapeutics during the 2nd quarter valued at approximately $1,757,000. SG Americas Securities LLC purchased a new stake in Rapport Therapeutics in the 3rd quarter worth $101,000. Finally, Values First Advisors Inc. purchased a new stake in Rapport Therapeutics in the 3rd quarter worth $31,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.